Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved for the treatment of patients with active relapsing-remitting MS (RRMS) defined by clinical or imaging features. This evidence concerns the gene CD52 and relapsing-remitting multiple sclerosis.